Allogene Advances Off-The-Shelf Mission With Pivotal Trial Progress, Solid Tumor Data
Early Renal Cell Carcinoma Results Offer Proof-Of-Concept
R&D head Zachary Roberts spoke with Scrip about Allogene’s Phase II pivotal trial for ALLO-501A and the firm’s hopes for overcoming challenges with allogeneic CAR-T therapies in solid tumors.